FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381612502> ?p ?o ?g. }

• W4381612502 abstract "Abstract Study question Can matrix-free culture system supplemented with Neurotrophic factor 4 (NT4) improve human follicular development and achieve mature and fertile oocytes in vitro? Summary answer NT4 promotes the growth, steroid hormone production of human secondary follicles cultured in vitro (including post- and pre-pubertal patients), thereby yielding mature and fertile oocytes. What is known already Reconstituting folliculogenesis in vitro play vital roles in reproductive biology research, fertility preservation and reproductive toxicity testing. However, fertile oocyte from in-vitro-grown (IVG) human follicle remains unachieved. It has been demonstrated that NT4 promotes in-vitro survival, growth, and maturation of mice secondary follicles. NT4 and its receptors have been detected in human ovaries. However, if the advance proved in mice model is effective to replicate in human has not been reported. Study design, size, duration Discarded ovarian tissues after ovarian tissue cryopreservation (OTC) were collected from 6 patients aged from 11 to 21 years old who underwent unilateral oophorectomy for fertility preservation, after obtaining written informed consent. Isolated secondary follicles were cultured in vitro with or without NT4 in a matrix-free system for 4-6 weeks individually. Participants/materials, setting, methods Secondary follicles isolated from each patient were randomly assigned to control or NT4 group, followed by incubation on the ultra-low attachment microplate individually. Follicle growth and survival were assessed by microscopy. Anti-Müllerian hormone (AMH), estradiol and progesterone levels were quantified in the medium. Oocyte marker expression was evaluated by DEAD box polypeptide 4 (Ddx4) staining. Oocyte mature and fertile potential were assessed by in-vitro maturation and intracytoplasmic sperm injection (ICSI) with donated sperm, separately. Main results and the role of chance In control condition, isolated follicles survived for 4-6 weeks with increased diameters over time (P &lt; 0.05), reaching a terminal diameter of 967.00 ± 41.1 μm with the confirmed induction of steroidogenesis and expression of widely accepted oocyte markers (DDX4). Three out of twelve (25%) alive follicles were matured successfully in vitro, most of which produced morphologically normal MII oocytes with sizes of 120 ± 2.1 μm. The diameter and steroid hormone production were significantly higher in the group cultured with NT4 than in the control group (P &lt; 0.05). An increased efficiency of MII oocyte production in the NT4 group was also observed, while the difference was not statistically significant. MII oocyte obtained from the control group showed abnormal fertilization after ICSI. In contrast, MII oocyte acquired from the NT4 group progressed to available blastocyst. Limitations, reasons for caution The population included were all patients with thalassemia. Whether this culture system is effective for patients with other diseases is unknown. Limited by the small sample, the effect of NT4 on maturation competence needs further confirmation. Oocytes obtained have not been quantified with ploidy status and epigenetic signatures. Wider implications of the findings Surplus ovarian tissue after OTC, which is otherwise discarded, may serve as an additional precious source of fertile oocytes for fertility preservation, even for pre-pubertal girls, without a threat of tumor reintroduction. The system described here will provide a powerful research tool for reproductive biology research and reproductive toxicity testing. Trial registration number not applicable" @default.
• W4381612502 created "2023-06-23" @default.
• W4381612502 creator A5008333363 @default.
• W4381612502 creator A5018445612 @default.
• W4381612502 creator A5037255399 @default.
• W4381612502 creator A5041468292 @default.
• W4381612502 creator A5056859770 @default.
• W4381612502 creator A5090935475 @default.
• W4381612502 date "2023-06-01" @default.
• W4381612502 modified "2023-09-23" @default.
• W4381612502 title "P-394 Neurotrophin-4 supplementation during human secondary follicle in-vitro-culture supports morphologically normal blastocyst formation" @default.
• W4381612502 doi "https://doi.org/10.1093/humrep/dead093.200" @default.
• W4381612502 hasPublicationYear "2023" @default.
• W4381612502 type Work @default.
• W4381612502 citedByCount "0" @default.
• W4381612502 crossrefType "journal-article" @default.
• W4381612502 hasAuthorship W4381612502A5008333363 @default.
• W4381612502 hasAuthorship W4381612502A5018445612 @default.
• W4381612502 hasAuthorship W4381612502A5037255399 @default.
• W4381612502 hasAuthorship W4381612502A5041468292 @default.
• W4381612502 hasAuthorship W4381612502A5056859770 @default.
• W4381612502 hasAuthorship W4381612502A5090935475 @default.
• W4381612502 hasBestOaLocation W43816125021 @default.
• W4381612502 hasConcept C102570824 @default.
• W4381612502 hasConcept C126322002 @default.
• W4381612502 hasConcept C134018914 @default.
• W4381612502 hasConcept C16685009 @default.
• W4381612502 hasConcept C179933525 @default.
• W4381612502 hasConcept C187785154 @default.
• W4381612502 hasConcept C196843134 @default.
• W4381612502 hasConcept C2775966511 @default.
• W4381612502 hasConcept C2776690073 @default.
• W4381612502 hasConcept C2777904497 @default.
• W4381612502 hasConcept C2778177303 @default.
• W4381612502 hasConcept C2780536345 @default.
• W4381612502 hasConcept C2908647359 @default.
• W4381612502 hasConcept C512716672 @default.
• W4381612502 hasConcept C518429986 @default.
• W4381612502 hasConcept C5512455 @default.
• W4381612502 hasConcept C71924100 @default.
• W4381612502 hasConcept C86803240 @default.
• W4381612502 hasConcept C87073359 @default.
• W4381612502 hasConcept C95444343 @default.
• W4381612502 hasConcept C99454951 @default.
• W4381612502 hasConceptScore W4381612502C102570824 @default.
• W4381612502 hasConceptScore W4381612502C126322002 @default.
• W4381612502 hasConceptScore W4381612502C134018914 @default.
• W4381612502 hasConceptScore W4381612502C16685009 @default.
• W4381612502 hasConceptScore W4381612502C179933525 @default.
• W4381612502 hasConceptScore W4381612502C187785154 @default.
• W4381612502 hasConceptScore W4381612502C196843134 @default.
• W4381612502 hasConceptScore W4381612502C2775966511 @default.
• W4381612502 hasConceptScore W4381612502C2776690073 @default.
• W4381612502 hasConceptScore W4381612502C2777904497 @default.
• W4381612502 hasConceptScore W4381612502C2778177303 @default.
• W4381612502 hasConceptScore W4381612502C2780536345 @default.
• W4381612502 hasConceptScore W4381612502C2908647359 @default.
• W4381612502 hasConceptScore W4381612502C512716672 @default.
• W4381612502 hasConceptScore W4381612502C518429986 @default.
• W4381612502 hasConceptScore W4381612502C5512455 @default.
• W4381612502 hasConceptScore W4381612502C71924100 @default.
• W4381612502 hasConceptScore W4381612502C86803240 @default.
• W4381612502 hasConceptScore W4381612502C87073359 @default.
• W4381612502 hasConceptScore W4381612502C95444343 @default.
• W4381612502 hasConceptScore W4381612502C99454951 @default.
• W4381612502 hasIssue "Supplement_1" @default.
• W4381612502 hasLocation W43816125021 @default.
• W4381612502 hasOpenAccess W4381612502 @default.
• W4381612502 hasPrimaryLocation W43816125021 @default.
• W4381612502 hasRelatedWork W1954131684 @default.
• W4381612502 hasRelatedWork W2017666327 @default.
• W4381612502 hasRelatedWork W2028417801 @default.
• W4381612502 hasRelatedWork W2039597999 @default.
• W4381612502 hasRelatedWork W2137155278 @default.
• W4381612502 hasRelatedWork W2146511467 @default.
• W4381612502 hasRelatedWork W2155255557 @default.
• W4381612502 hasRelatedWork W2172116462 @default.
• W4381612502 hasRelatedWork W2401943237 @default.
• W4381612502 hasRelatedWork W2595278892 @default.
• W4381612502 hasVolume "38" @default.
• W4381612502 isParatext "false" @default.
• W4381612502 isRetracted "false" @default.
• W4381612502 workType "article" @default.